Antisecretory drugs, Helicobacter pylori infection and symptom relief in GORD: still an unexplored triangle.
Scarpignato
C
C
Laboratory of Clinical Pharmacology, School of Medicine and Dentistry, University of Parma, Italy. scarpi@tin.it
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D004942:Esophagitis, Peptic / Q000188:drug therapy; D015738:Famotidine / Q000008:administration & dosage; D005764:Gastroesophageal Reflux / Q000188:drug therapy* / Q000382:microbiology*; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006635:Histamine H2 Antagonists / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D064747:Lansoprazole; D009853:Omeprazole / Q000008:administration & dosage / Q000031:analogs & derivatives; D054328:Proton Pump Inhibitors; D011788:Quality of Life
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D006635:Histamine H2 Antagonists; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; D015738:Famotidine; D009853:Omeprazole